NCT06873425尚未招募不适用
A Study on the Safety and Effectiveness of Limosilactobacillus Fermentum LF61 in Improving Intestinal and Immune Functions
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Change of concentration of antimicrobial peptide LL-37
研究概览
简要总结
Evaluate the effectiveness and safety of Limosilactobacillus fermentum LF61 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing to undergo 3 follow-up visits during the intervention period
- •Be willing to provide blood, urine and stool samples 2 times during the intervention period
- •Willing to self-administer one of the 7 probiotics (BI45, BBi32, LS97, LB42, LF61, LH76, LR08)/placebo once a day during the intervention period
- •Good eyesight, can read and write, can wear glasses
- •Have good hearing and be able to hear and understand all instructions during the intervention -
排除标准
- •Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
- •Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
- •Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
- •Take medication for depression or low mood
- •Internal organ failure (heart, liver or kidney failure, etc.)
- •Have received radiation or chemotherapy in the past
- •have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
- •Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past -
研究组 & 干预措施
Placebo group
Placebo Comparator
Every day to give 3 g maltodextrin intervention for 8 weeks.
干预措施: Placebo (Dietary Supplement)
Probiotic group
Active Comparator
Intervention with Limosilactobacillus fermentum LF61 (30 billion CFU/ day, 3g) was administered daily for 8 weeks.
干预措施: Probiotic (Dietary Supplement)
结局指标
主要结局
Change of concentration of antimicrobial peptide LL-37
时间窗: Week 0 and Week 8
Detected by Enzyme-Linked Immunosorbent Assay (ELISA).
Change in calcarein concentration
时间窗: Week 0 and Week 8
Detected by Enzyme-Linked Immunosorbent Assay (ELISA).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effects of Limicol on LDL-cholesterolHypercholesteremiaNCT01354327Lescuyer Laboratory47
招募中
不适用
Clinical Effects of Limosilactobacillus Reuteri Probiotics as an Adjunct to the Treatment of PeriodontitisChronic Periodontitis, GeneralizedNCT05734274Universidade do Porto60
已完成
不适用
Levilactobacillus Brevis Oral HealthOral HealthOral DiseaseNCT06457724University of L'Aquila70
终止
不适用
Effect of Probiotics on Recurrent Urinary Tract InfectionsUrinary Tract InfectionsNCT06192966AB Biotics, SA106
已完成
不适用
The Effect of Probiotics on the Improvement of Intestinal and Immune FunctionIntestinal and Immune Function ImprovedNCT06873438Wecare Probiotics Co., Ltd.52